Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

Somnath Mukherjee,Chris Nicholas Hurt,Catrin Cox,Ganesh Radhakrishna,Sarah Gwynne,Andrew Bateman,Simon Gollins,Maria A. Hawkins,Jo Canham,Heike I. Grabsch,Stephen Falk,Ricky A. Sharma,Ruby Ray,Rajarshi Roy,Wendy Wade,R. Maggs,David Sebag-Montefiore,Tim Maughan,Gareth Griffiths,Tom Crosby

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

2020

373Background: Initial results of the NEOSCOPE trial comparing pre-operative CarPac vs OxCap based chemoradiotherapy (CRT) in patients with adenocarcinoma of the oesophagus or oesophagogastric junc...

Keywords:

esophageal adenocarcinoma
Carboplatin/paclitaxel
Survival analysis
Oxaliplatin
Internal medicine
Oncology
Medicine
Capecitabine
Pathology
in patient
Adenocarcinoma
Chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations